Leukos Biotech is a spin-off company form the Josep Carreras Leukaemia Research Institute.

We focus on developing new treatments and diagnostic tools for Leukaemia.

We have identified a new therapeutic target against Leukemic Stem Cells in AML which will be validated, using a repurposed small molecule, in a Phase II clinical trial starting at the beginning of 2019. The study will also cover the diagnosis and prognosis of AML patients according to the expression of this biomarker in blood.